Evidence map›Paper›PMID 33507942›Full record

ArticlePloS one2021

Polymer-assisted intratumoral delivery of ethanol: Preclinical investigation of safety and efficacy in a murine breast cancer model.

Corrine Nief, Robert Morhard, Erika Chelales, Daniel Adrianzen Alvarez, Ioanna Bourla Bs, Christopher T Lam, Alan A Sag, Brian T Crouch, Jenna L Mueller, David Katz and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Corrine NiefDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0003-3870-4786
Robert MorhardDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.
Erika ChelalesDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.
Daniel Adrianzen AlvarezDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.
Ioanna Bourla BsDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.
Christopher T LamDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.
Alan A SagDepartment of Interventional Radiology, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0002-3106-0458
Brian T CrouchDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0002-2310-6110
Jenna L MuellerDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.
David KatzDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.
Mark W DewhirstDepartment of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina, United States of America.
Jeffrey I EverittDepartment of Pathology, Duke University, Durham, North Carolina, United States of America.
Nirmala RamanujamDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America.
Duke University · US

Funding

Novel see and treat strategies for cervical cancer prevention in low-resource settingsR01CA239268 · NCI · DUKE UNIVERSITY · PI KATZ, DAVID FRANK, RAMANUJAM, NIRMALA · 2019 to 2023
$3.1M
NCI NIH HHS R01 CA239268
6 · The paper itself

Abstract

Focal tumor ablation with ethanol could provide benefits in low-resource settings because of its low overall cost, minimal imaging technology requirements, and acceptable clinical outcomes. Unfortunately, ethanol ablation is not commonly utilized because of a lack of predictability of the ablation zone, caused by inefficient retention of ethanol at the injection site. To create a predictable zone of ablation, we have developed a polymer-assisted ablation method using ethyl cellulose (EC) mixed with ethanol. EC is ethanol-soluble and water-insoluble, allowing for EC-ethanol to be injected as a liquid and precipitate into a solid, occluding the leakage of ethanol upon contact with tissue. The aims of this study were to compare the 1) safety, 2) release kinetics, 3) spatial distribution, 4) necrotic volume, and 5) overall survival of EC-ethanol to conventional ethanol ablation in a murine breast tumor model. Non-target tissue damage was monitored through localized adverse events recording, ethanol release kinetics with Raman spectroscopy, injectate distribution with in vivo imaging, target-tissue necrosis with NADH-diaphorase staining, and overall survival by proxy of tumor growth. EC-ethanol exhibited decreased localized adverse events, a slowing of the release rate of ethanol, more compact injection zones, 5-fold increase in target-tissue necrosis, and longer overall survival rates compared to the same volume of pure ethanol. A single 150 μL dose of 6% EC-ethanol achieved a similar survival probability rates to six daily 50 μL doses of pure ethanol used to simulate a slow-release of ethanol over 6 days. Taken together, these results demonstrate that EC-ethanol is safer and more effective than ethanol alone for ablating tumors.

Indexed as

AnimalsApoptosisBreast NeoplasmsCell ProliferationCentral Nervous System DepressantsEthanolFemaleHumansMiceMice, Inbred BALB CMice, NudeTumor Cells, CulturedXenograft Model Antitumor AssaysCentral Nervous System DepressantsEthanol

Identifiers

PMID33507942
PMCPMC7843014
OpenAlexW3123000185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.